Revmedica

What Revmedica does

Revmedica (legal name RevMedica, Inc.) is a private MedTech company founded in 2017 by Thomas Wenchell and headquartered in Middletown, Connecticut. The company is developing a single integrated product, the Endo Stapling Platform — a patent-protected, ergonomically designed powered laparoscopic stapler that combines motorized firing with real-time tissue sensing and assessment to provide surgeons objective, intraoperative feedback during minimally invasive and robotic soft tissue procedures, particularly in gastrointestinal surgery.

The platform's differentiator is its real-time actionable insight technology, which characterizes tissue properties prior to and during stapler firing to optimize staple formation and reduce complications such as leaks. RevMedica has built a defensible IP position with 20 issued US patents, 5 foreign patents, and 11 pending US applications, and is the only surgical stapling device accepted into the FDA's Safer Technologies Program (STeP), which provides expedited regulatory review. The company has also entered a non-exclusive data partnership with Qaelon Medical to integrate real-time leak detection telemetry with its stapling data for clinical validation and claims development.

Commercially, Revmedica has not yet received FDA clearance and has no reported revenue. Its planned go-to-market is enterprise field sales targeting hospitals and ambulatory surgical centers, led by CCO Steve Lampkin (appointed 2024). Revenue mechanics will follow the traditional surgical stapler model of capital equipment placement plus recurring disposable cartridge sales. The company has raised approximately $14.16M via a 2023 SEC Rule 506(b) offering (41 investors) led by Telegraph Hill Partners, with additional non-dilutive support from a 2021 NSF grant, and operates with 11-50 employees.

Name

Revmedica

Legal name

RevMedica, Inc.

Website

https://revmedica.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Revmedica is a pre-commercial MedTech company developing the Endo Stapling Platform, a powered laparoscopic stapler with real-time tissue sensing for minimally invasive and robotic gastrointestinal surgery. It targets hospitals and surgical centers and is awaiting FDA clearance following STeP acceptance.

Ownership category

akta.pro rank

Product category

Surgical Stapling Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro industry

PRIMARYHLAHADAA

Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

SECONDARYHLAHADAF

Surgical Robotics & Computer-Assisted Surgery Platforms

Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

• Surgical stapling devices
• Laparoscopic surgical instruments
• Minimally invasive surgery
• Soft tissue management
• Robotic surgical platforms

Headquarters

HQ city

Middletown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Surgical Stapling Devices and Platform: Revenue derived from the sale of the RevMedica Endo Stapling Platform and associated surgical stapling devices. The company is preparing for US commercial launch of its powered laparoscopic stapler. Both RevMedica and Qaelon Medical products are under development and have not yet been cleared by the FDA.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Revmedica develops the Endo Stapling Platform, a patent-protected, handheld robotic surgical stapling system for soft tissue management in minimally invasive and robotic surgery. The platform integrates objective real-time tissue sensing and intraoperative assessment to deliver actionable data to surgeons during stapling procedures. It is designed for acute care hospitals, ambulatory surgical centers, and gastrointestinal/endoscopic surgeons, with the powered laparoscopic stapler being prepared for US commercial launch.

Product overview

RevMedica offers a single unified product platform called the Endo Stapling Platform. This novel, patent-protected technology is designed for minimally invasive and robotic surgery, providing digital precision and real-time tissue feedback during surgical stapling procedures. The platform aims to optimize clinical decision-making, improve patient safety, and deliver economic and environmental value through cost-effective, environmentally friendly surgical systems.

Differentiator

Problem solved

Functional benefit

Brands

• Endo Stapling Platform: Digital precision and real-time feedback for minimally invasive procedures, optimizing staple formation and tissue management.

Products and services

• Endo Stapling Platform A novel, patent-protected surgical stapling platform providing digital precision and real-time feedback for minimally invasive and robotic procedures by optimizing staple formation and tissue management. It delivers intraoperative intelligence to optimize surgical decision-making while enhancing OR workflows and reducing waste. Targeted at acute care hospitals, ambulatory surgical centers, and gastrointestinal/endoscopic surgeons.

Quantifiable outcome

• Both RevMedica and Qaelon Medical technologies have been selected for FDA's Safer Technologies Program (STeP)

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

One partnership is on record.

• Qaelon MedicalcoreStrategic or Co-development Partner · 6 March 2025Non-exclusive data partnership to improve stapler performance and clinical outcomes in gastrointestinal surgery. Integration of RevMedica's advanced stapling technology with Qaelon's real-time leak detection and performance data. Objectives include accelerating product development and validation, assessing tissue properties impact on staple line performance, and assisting with regulatory approvals and claims development. Both companies' technologies are in FDA's Safer Technologies Program (STeP).

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Medtronic: Medtronic (via Covidien) is the dominant surgical stapling player with the Signia powered stapler and Endo GIA reload portfolio. Most directly comparable incumbent competing head-to-head for laparoscopic/robotic GI stapling volume with far greater scale and an installed base.
• Ethicon (Johnson & Johnson MedTech): Ethicon's Echelon Flex GST powered stapler family is the other category leader. Directly competes in laparoscopic and robotic-assisted GI stapling, with broad hospital procurement contracts and surgeon training infrastructure.
• Standard Bariatrics (Teleflex): Acquired by Teleflex in 2022, Standard Bariatrics developed the Titan SGS powered stapling platform for bariatric/foregut surgery. Closest pure-play peer to RevMedica's powered-stapler approach in a sub-specialty of the GI stapling market.

Broad incumbents

• Intuitive Surgical: Dominant robotic surgery platform (da Vinci) used in the same GI laparoscopic procedures where RevMedica's stapler would be deployed. Sets the standard for what 'intelligent' minimally invasive surgery looks like and is a likely acquirer of point-tool innovators.
• Stryker: Large-cap MedTech with a surgical instruments and endoscopy portfolio (and digital surgery investments). Represents a potential strategic acquirer and a competitor in hospital capital-equipment and disposable sales channels.
• B. Braun: Diversified medical device manufacturer with an Aesculap surgical instruments and endoscopy portfolio selling into the same hospital/surgical-center channel. Represents another large-cap competitor and potential strategic acquirer.

Emerging players

• Vicarious Surgical: Emerging robotic surgery platform focused on minimally invasive abdominal procedures. Competes with RevMedica for the same GI surgical workflows, though at the robotic-system layer rather than the stapling-tool layer.
• Asensus Surgical: Digital laparoscopy / surgical robotics company with the Senhance platform and a stated focus on digital surgery intelligence. Comparable to RevMedica's 'intraoperative intelligence' positioning in the same minimally invasive GI surgery workflow.
• Moon Surgical: Robotic-assisted laparoscopic surgery platform (Maestro) aimed at the OR-assistant layer of laparoscopic procedures. Comparable emerging competitor for surgeon mindshare and OR workflow integration in GI laparoscopy.
• LivsMed: Developer of ArtiSential articulating laparoscopic instruments. Adjacent emerging competitor in the same minimally invasive soft-tissue management category, targeting similar surgeon ergonomics and precision gains.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/revmedica-inc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Revmedica